Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2017 Filed Dec 11, 2017 21:15 UTC |
Donini OreolaSVP and CSO
|
GrantOption (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001213900-17-013087 · f4120717donini_soligenix.xml · derivative · entry 1 Donini Oreola · CIK 0001627575 · SVP and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-12-06 F1 · security: The stock option vested immediately as to 8,750 shares and vests as to the remainder at a rate of 2,187.5 of the shares on each three (3) month anniversary of December 7, 2017. F1 · derivative.exercise_date: The stock option vested immediately as to 8,750 shares and vests as to the remainder at a rate of 2,187.5 of the shares on each three (3) month anniversary of December 7, 2017. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC |
Essetifin SPAFormer 10% Owner
CAVAZZA PAOLOFormer 10% Owner
Leadiant Biosciences, Inc.Former 10% Owner
Cavazza EnricoFormer 10% Owner
Cavazza FrancescaFormer 10% Owner
Cavazza SilviaFormer 10% Owner
Cavazza Preta MartinaFormer 10% Owner
|
PurchaseCommon Stock | 16,416 | $2.12 | $34,801.92 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 6 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,510 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F5 · balance_after: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F5 · ownership.direct: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC |
Essetifin SPAFormer 10% Owner
CAVAZZA PAOLOFormer 10% Owner
Leadiant Biosciences, Inc.Former 10% Owner
Cavazza EnricoFormer 10% Owner
Cavazza FrancescaFormer 10% Owner
Cavazza SilviaFormer 10% Owner
Cavazza Preta MartinaFormer 10% Owner
|
SaleCommon Stock | 16,416 | $2.12 | $34,801.92 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 5 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F5 · balance_after: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F5 · ownership.direct: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. F5 · ownership.nature: Sold by Sinaf and purchased by Essetifin S.p.A., an Italian corporation ("Essetifin"), pursuant to a purchase agreement by and between Essetifin and Sinaf. Paolo Cavazza previously reported indirect ownership of such shares due to his ownership interests in Sinaf, which is a directly wholly-owned subsidiary of Aptafin S.p.A., which is owned indirectly by Paolo Cavazza and members of his family. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC |
Essetifin SPAFormer 10% Owner
CAVAZZA PAOLOFormer 10% Owner
Leadiant Biosciences, Inc.Former 10% Owner
Cavazza EnricoFormer 10% Owner
Cavazza FrancescaFormer 10% Owner
Cavazza SilviaFormer 10% Owner
Cavazza Preta MartinaFormer 10% Owner
|
PurchaseCommon Stock | 5,954 | $2.12 | $12,622.48 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 4 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,094 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F4 · balance_after: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F4 · ownership.direct: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC |
Essetifin SPAFormer 10% Owner
CAVAZZA PAOLOFormer 10% Owner
Leadiant Biosciences, Inc.Former 10% Owner
Cavazza EnricoFormer 10% Owner
Cavazza FrancescaFormer 10% Owner
Cavazza SilviaFormer 10% Owner
Cavazza Preta MartinaFormer 10% Owner
|
SaleCommon Stock | 5,954 | $2.12 | $12,622.48 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 3 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F4 · balance_after: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F4 · ownership.direct: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. F4 · ownership.nature: Sold by Paolo Cavazza and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and Paolo Cavazza. Paolo Cavazza previously reported direct ownership of such shares and continues to have an indirect interest through his ownership interest in Essetifin. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC |
Essetifin SPAFormer 10% Owner
CAVAZZA PAOLOFormer 10% Owner
Leadiant Biosciences, Inc.Former 10% Owner
Cavazza EnricoFormer 10% Owner
Cavazza FrancescaFormer 10% Owner
Cavazza SilviaFormer 10% Owner
Cavazza Preta MartinaFormer 10% Owner
|
PurchaseCommon Stock | 271,140 | $2.12 | $574,816.80 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 2 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,140 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer. F3 · balance_after: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F3 · ownership.direct: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. Read SEC document |
| November 29, 2017 Filed Dec 1, 2017 21:25 UTC |
Essetifin SPAFormer 10% Owner
CAVAZZA PAOLOFormer 10% Owner
Leadiant Biosciences, Inc.Former 10% Owner
Cavazza EnricoFormer 10% Owner
Cavazza FrancescaFormer 10% Owner
Cavazza SilviaFormer 10% Owner
Cavazza Preta MartinaFormer 10% Owner
|
SaleCommon Stock | 271,140 | $2.12 | $574,816.80 |
DisclosureSEC source: 0001213900-17-012851 · f4112917essetifin_soligenix.xml · nonDerivative · entry 1 Essetifin SPA · CIK 0001092601 · Former 10% Owner CAVAZZA PAOLO · CIK 0001163608 · Former 10% Owner Leadiant Biosciences, Inc. · CIK 0001385625 · Former 10% Owner Cavazza Enrico · CIK 0001525744 · Former 10% Owner Cavazza Francesca · CIK 0001525742 · Former 10% Owner Cavazza Silvia · CIK 0001525743 · Former 10% Owner Cavazza Preta Martina · CIK 0001718557 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 0 F1 · shares: Effective October 7, 2016, the issuer completed a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, whereby every 10 shares of its common stock were exchanged for one share of its common stock (the "Reverse Stock Split"). These shares have been adjusted to reflect the Reverse Stock Split. F2 · balance_after: This Form 4 reflects the transfer of shares of common stock by each of (i) Leadiant Biosciences, Inc., formerly Sigma Tau Pharmaceuticals Inc., a Nevada corporation ("LBI"); (ii) Paolo Cavazza; and (iii) Sinaf S.A., a Luxembourg corporation ("Sinaf"), to Essetifin S.p.A., formerly Sigma Tau Finanziaria S.p.A., an Italian corporation ("Essetifin"). Each transaction is reported as a disposition by the respective seller and an acquisition of the same amount of shares by Essetifin. After giving effect to these transactions, Essetifin beneficially owns an aggregate of 293,510 shares of common stock of the issuer. F3 · balance_after: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F3 · ownership.direct: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. F6 · ownership.direct: Dispositive power over the shares of common stock owned by Essetifin is shared by Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza. Each of Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta and Paolo Cavazza disclaims beneficial ownership of all shares of common stock held by Essetifin except to the extent of any pecuniary interest therein. F3 · ownership.nature: Sold by LBI and purchased by Essetifin pursuant to a purchase agreement by and between Essetifin and LBI. Each of Essetifin and Paolo Cavazza previously reported indirect ownership of such shares due to their respective ownership interests in LBI. Paolo Cavazza continues to have an indirect interest in such shares through his ownership interest in Essetifin. After the purchase of these shares by Essetifin, LBI no longer directly holds common stock of the issuer. LBI directly owns warrants to purchase shares of the issuer's common stock. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:21 UTC |
Brownlie Keith LDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006383 · f4060817brownlie_soligenix.xml · derivative · entry 1 Brownlie Keith L · CIK 0001518575 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:21 UTC |
Brughera Marco MariaDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006382 · f4060817brughera_soligenix.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:21 UTC |
LAPOINTE ANTHONY GREGGDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006381 · f4060817lapointe_soligenix.xml · derivative · entry 1 LAPOINTE ANTHONY GREGG · CIK 0001331860 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:20 UTC |
RUBIN ROBERT J.Director
|
GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006380 · f4060817rubin_soligenix.xml · derivative · entry 1 RUBIN ROBERT J. · CIK 0001413631 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:20 UTC |
ZELDIS JEROME BDirector
|
GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006379 · f4060817zeldis_soligenix.xml · derivative · entry 1 ZELDIS JEROME B · CIK 0001433982 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| May 08, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 1,881 | $2.54 | $4,777.74 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 8 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by Intrexon Disclosed balance after: 85,397 F3 · shares: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F3 · price: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F5 · ownership.nature: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 08, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 9,695 | $2.54 | $24,625.30 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 5 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by NRM VII Holdings Disclosed balance after: 440,418 F3 · shares: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F3 · price: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F4 · ownership.nature: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 05, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 13,893 | $2.70 | $37,511.10 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 7 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by Intrexon Disclosed balance after: 87,278 F3 · shares: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F3 · price: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F5 · ownership.nature: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 05, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 71,607 | $2.70 | $193,338.90 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 4 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by NRM VII Holdings Disclosed balance after: 450,113 F3 · shares: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F3 · price: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F4 · ownership.nature: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
OtherWarrant to Purchase Common Stock · Derivative | 250,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · derivative · entry 9 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by NRM VII Holdings Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2018-06-25 F1 · shares: The indicated share amount is reflective of a 1:10 reverse stock split effected by the issuer on October 7, 2016. F4 · ownership.nature: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 2,278 | $2.97 | $6,765.66 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 6 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by Intrexon Disclosed balance after: 101,171 F3 · shares: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F3 · price: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F1 · balance_after: The indicated share amount is reflective of a 1:10 reverse stock split effected by the issuer on October 7, 2016. F5 · ownership.nature: Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 11,739 | $2.97 | $34,864.83 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 3 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by NRM VII Holdings Disclosed balance after: 521,720 F3 · shares: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F3 · price: Pursuant to a joint selling program, NRM VII Holdings I, LLC ("NRM VII Holdings") and Intrexon Corporation ("Intrexon") sold shares on a pro rata basis. F4 · ownership.nature: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
SaleCommon Stock | 49,875 | $4.01 | $199,998.75 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 2 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by NRM VII Holdings Disclosed balance after: 533,459 F2 · shares: Shares surrendered to the issuer in order to satisfy the exercise price in connection with the cashless exercise of a warrant to purchase 250,000 shares of common stock of the issuer. F4 · ownership.nature: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 21:30 UTC |
KIRK RANDAL J10% owner
PRECIGEN, INC.10% owner
|
OtherCommon Stock | 250,000 | $0.80 | $200,000.00 |
DisclosureSEC source: 0001140361-17-018903 · doc1.xml · nonDerivative · entry 1 KIRK RANDAL J · CIK 0001091823 · 10% owner INTREXON CORP · CIK 0001356090 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · by NRM VII Holdings Disclosed balance after: 583,334 F1 · balance_after: The indicated share amount is reflective of a 1:10 reverse stock split effected by the issuer on October 7, 2016. F4 · ownership.nature: Randal J. Kirk controls NRM VII Holdings. Shares held by this entity may be deemed to be indirectly beneficially owned (as defined under Rule 13d- 3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:17 UTC |
Straube RichardSVP and CMO
|
GrantOption (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-17-003325 · f4033117straube_soligenix.xml · derivative · entry 1 Straube Richard · CIK 0001595197 · SVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 F1 · security: The stock option vested immediately as to 5,000 shares and vests as to the remainder at a rate of 1,250 of the shares on each three (3) month anniversary of March 31, 2017. F1 · derivative.exercise_date: The stock option vested immediately as to 5,000 shares and vests as to the remainder at a rate of 1,250 of the shares on each three (3) month anniversary of March 31, 2017. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:16 UTC |
SCHABER CHRISTOPHER JDirector · Chairman, CEO and President
|
GrantOption (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-17-003324 · f4033117schaber_soligenix.xml · derivative · entry 1 SCHABER CHRISTOPHER J · CIK 0001068029 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-03-30 F1 · security: The stock option vested immediately as to 12,500 shares and vests as to the remainder at a rate of 3,125 of the shares on each three (3) month anniversary of March 31, 2017. F1 · derivative.exercise_date: The stock option vested immediately as to 12,500 shares and vests as to the remainder at a rate of 3,125 of the shares on each three (3) month anniversary of March 31, 2017. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:15 UTC |
Donini OreolaSVP and CSO
|
GrantOption (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-17-003321 · f4033117donini_soligenix.xml · derivative · entry 1 Donini Oreola · CIK 0001627575 · SVP and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 F1 · security: The stock option vested immediately as to 5,000 shares and vests as to the remainder at a rate of 1,250 of the shares on each three (3) month anniversary of March 31, 2017. F1 · derivative.exercise_date: The stock option vested immediately as to 5,000 shares and vests as to the remainder at a rate of 1,250 of the shares on each three (3) month anniversary of March 31, 2017. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 20:16 UTC |
Krumeich Karen RSVP and CFO
|
GrantOption (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-17-003323 · f4033117krumeich_soligenix.xml · derivative · entry 1 Krumeich Karen R · CIK 0001334797 · SVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-03-30 F1 · security: The stock option vested immediately as to 5,000 shares and vests as to the remainder at a rate of 1,250 of the shares on each three (3) month anniversary of March 31, 2017. F1 · derivative.exercise_date: The stock option vested immediately as to 5,000 shares and vests as to the remainder at a rate of 1,250 of the shares on each three (3) month anniversary of March 31, 2017. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:01 UTC |
RUBIN ROBERT J.Director
|
PurchaseCommon Stock Warrant · Derivative | 3,956 | $0.00 Strike: $3.95 | $0.40 |
DisclosureSEC source: 0001213900-16-019533 · f4121616rubin_soligenix.xml · derivative · entry 2 RUBIN ROBERT J. · CIK 0001413631 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,956 Underlying: Common Stock · 3,956 shares Expires 2021-12-15 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:01 UTC |
RUBIN ROBERT J.Director
|
PurchaseCommon Stock | 3,165 | $3.16 | $10,001.08 |
DisclosureSEC source: 0001213900-16-019533 · f4121616rubin_soligenix.xml · nonDerivative · entry 1 RUBIN ROBERT J. · CIK 0001413631 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,385 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:02 UTC |
SCHABER CHRISTOPHER JDirector · Chairman, CEO and President
|
PurchaseCommon Stock Warrant · Derivative | 19,755 | $0.00 Strike: $3.95 | $1.98 |
DisclosureSEC source: 0001213900-16-019534 · f4121616schaber_soligenix.xml · derivative · entry 2 SCHABER CHRISTOPHER J · CIK 0001068029 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,755 Underlying: Common Stock · 19,755 shares Expires 2021-12-15 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:02 UTC |
SCHABER CHRISTOPHER JDirector · Chairman, CEO and President
|
PurchaseCommon Stock | 15,804 | $3.16 | $49,939.06 |
DisclosureSEC source: 0001213900-16-019534 · f4121616schaber_soligenix.xml · nonDerivative · entry 1 SCHABER CHRISTOPHER J · CIK 0001068029 · Director · Chairman, CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,095 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:00 UTC |
Brughera Marco MariaDirector
|
PurchaseCommon Stock Warrant · Derivative | 2,500 | $0.00 Strike: $3.95 | $0.25 |
DisclosureSEC source: 0001213900-16-019532 · f4121616brughera_soligenix.xml · derivative · entry 2 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2021-12-15 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:00 UTC |
Brughera Marco MariaDirector
|
PurchaseCommon Stock | 2,000 | $3.16 | $6,319.80 |
DisclosureSEC source: 0001213900-16-019532 · f4121616brughera_soligenix.xml · nonDerivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.